article Open AccessTop 1% cited
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
Lara D. Veeken · 2009 · Vol. 49(2) · pp. 271–280
Dimitrios Daoussis✉(General University Hospital of Patras)Stamatis‐Nick C. Liossis(University of Patras)Athanassios C. Tsamandas(University of Patras)Christina Kalogeropoulou(University of Patras)Alexandra Kazantzi(University of Patras)Chaido Sirinian(University of Patras)Maria P. Karampetsou(University of Patras)Georgios Yiannopoulos(University of Patras)Andrew P. Andonopoulos(University of Patras)
Abstract
Our results indicate that RTX may improve lung function in patients with SSc. To confirm our encouraging results we propose that larger scale, multicentre studies with longer evaluation periods are needed.
Systemic Sclerosis and Related DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisDermatologic Treatments and ResearchMedicineDLCOInternal medicineVital capacityGastroenterologyRituximabPulmonary function testingDiffusing capacitySurgeryLung function
MeSH terms
RituximabAdultAgedB-LymphocytesBiopsyCollagenDrug Administration ScheduleHumansImmunosuppressive AgentsLymphocyte DepletionMiddle AgedRespiratory Function TestsScleroderma, SystemicSkinTomography, X-Ray Computed
Citations
392
FWCI
13.38
field-weighted impact
References
49
Percentile
99%
vs. same field & year
Citations per year
References
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Arthritis & Rheumatism · 1980 · 4,927 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.